<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03762031</url>
  </required_header>
  <id_info>
    <org_study_id>GTI-4711-002</org_study_id>
    <nct_id>NCT03762031</nct_id>
  </id_info>
  <brief_title>A Study Designed to Evaluate the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Dose Escalation Study Designed to Evaluate the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galera Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galera Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be a Phase 1, randomized, double-blind, placebo-controlled, single dose
      escalation study designed to evaluate the safety and PK of intravenously administered
      superoxide dismutase mimetic GC4711 in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2019</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events and Laboratory Abnormalities</measure>
    <time_frame>From randomization through study completion (estimated up to 3 days)</time_frame>
    <description>Number of Participants With Treatment-Emergent Adverse Events and/or Laboratory Abnormalities</description>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>GC4711 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GC4711 60mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GC4711 90mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GC4711 120mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GC4711 75mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GC4711 105mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC4711 30mg</intervention_name>
    <description>single dose given via a 15 minute intravenous infusion</description>
    <arm_group_label>GC4711 30mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC4711 60mg</intervention_name>
    <description>single dose given via a 15 minute intravenous infusion</description>
    <arm_group_label>GC4711 60mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC4711 90mg</intervention_name>
    <description>single dose given via a 15 minute intravenous infusion</description>
    <arm_group_label>GC4711 90mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC4711 120mg</intervention_name>
    <description>single dose given via a 15 minute intravenous infusion</description>
    <arm_group_label>GC4711 120mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single dose of normal saline given via a 15 minute intravenous infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC4711 75mg</intervention_name>
    <description>single dose given via a 15 minute intravenous infusion</description>
    <arm_group_label>GC4711 75mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC4711 105mg</intervention_name>
    <description>single dose given via a 15 minute intravenous infusion</description>
    <arm_group_label>GC4711 105mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy men and women between 18 and 50 years

          2. Subjects who provide written informed consent

          3. Body Mass Index (BMI) of 18 to 32 kg/m2 and weighing at least 50 kg

          4. Subjects in general good health

          5. Blood pressure and pulse within normal limits

          6. Male subjects must practice effective contraception

          7. Female subjects must:

               -  Have a negative serum pregnancy test during

               -  Be non-lactating;

               -  Be at least 2 years postmenopausal, surgically sterile, or practicing effective
                  contraception.

        Exclusion Criteria:

          1. History of clinically significant illness or medical history which would preclude them
             from the study.

          2. Known contraindication, hypersensitivity and/or allergy to study drugs

          3. Use of any prescription or over-the-counter medication within one week prior to study
             drug administration

          4. Anticipated need for any medication during the study

          5. Use of nitrates or erectile dysfunction drugs such as phosphodiesterase type 5 (PDE 5)
             inhibitors

          6. Use of other drugs that may, in the judgment of the Investigator, create a risk for a
             precipitous decrease in blood pressure

          7. Presence of orthostatic hypotension at screening

          8. Use of any vitamin or mineral supplement 24 hours before dosing or throughout study

          9. Positive human immunodeficiency virus (HIV), hepatitis B (HBV) or hepatitis C (HCV)

         10. Known history of substance abuse, drug addiction, or alcoholism within 3 years

         11. Anticipated inability to abstain from alcohol, tobacco, or caffeine use from 48 hours
             before the administration of study drug and throughout the the study;

         12. Positive drug and alcohol toxicology screens during Screening

         13. History of smoking or any use of a tobacco product within 6 months

         14. Donation of blood or blood products within 30 days before Baseline and throughout the
             study;

         15. Mentally unstable or incapable of being compliant with the protocol

         16. Receipt of an investigational test substance within 3 months before the administration
             of study drugs, or anticipated receiving any study drugs

         17. Subject has previously participated in this study, or in a prior Galera study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon Holmlund, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Galera Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kara Terry</last_name>
    <phone>610-725-1500</phone>
    <email>kterry@galeratx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nucleus Network</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>613 8593 9800</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>November 30, 2018</study_first_submitted>
  <study_first_submitted_qc>November 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2018</study_first_posted>
  <last_update_submitted>September 17, 2019</last_update_submitted>
  <last_update_submitted_qc>September 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

